Formulation Development
Ocean Biomedical Announces New Data Deepening Understanding of Novel Cancer Immunotherapy Treatment Approach
Ocean Biomedical recently announced Scientific Co-founder Dr. Jack A. Elias, MD, PhD, and colleagues have published new research in the Journal of Immunology that expands…
Sermonix Pharmaceuticals’ Lasofoxifene Demonstrates Anti-Estrogen Therapy Increases Immunotherapy Efficacy by Promoting Antitumor Activity of Eosinophils
Sermonix Pharmaceuticals Inc. recently announced its lead investigational drug, lasofoxifene, was featured in a new Duke Cancer Institute study revealing that anti-estrogen therapy increases the…
Tessellate BIO, Omico & CMRI Announce Multi-Year Collaboration
Tessellate BIO recently announced a collaboration with CMRI and Omico to advance the understanding of the prevalence of alternative lengthening of telomeres (ALT) across tumor…
Renaissance Lakewood Supports ARS Pharmaceuticals’ Launch of World’s First Nasal Spray for Life-Threatening Allergies
Renaissance Lakewood, LLC is proud to be manufacturing neffy, which is now commercially available in the US. On August 9, 2024, the US FDA approved ARS…
Prime Medicine Announces Strategic Research Collaboration & License Agreement With Bristol Myers Squibb
Prime Medicine, Inc. recently announced a strategic research collaboration and license agreement with Bristol Myers Squibb to develop reagents for the next generation of ex…
Enliven Therapeutics Announces Positive Data Update from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia
Enliven Therapeutics, Inc. recently announced updated, positive data from the Phase 1 clinical trial evaluating ELVN-001 in patients with chronic myeloid leukemia (CML) that has…
Traws Pharma Announces Positive Topline Phase 1 Results for COVID Candidate, an Oral Mpro Inhibitor
Traws Pharma, Inc. recently announced positive topline Phase 1 results for its potential best-in-class COVID (SARS-CoV-2) candidate, ratutrelvir, an oral inhibitor of the Main protease…
Adaptive Research Announces it has Begun Enrolling Patients in AriBio’s Phase 3 POLARIS-AD Clinical Trial
Adaptive Research recently announced two community practices that are part of the Adaptive Research network have begun patient enrollment and randomization in AriBio’s Phase 3, Double-blind,…
Ocuphire Pharma Announces Full Phase 3 Results of Phentolamine Ophthalmic Solution for Pharmacologically Induced Mydriasis in Ophthalmology
Ocuphire Pharma, Inc. recently announced the publication of full results from two pivotal Phase 3 clinical trials (MIRA-2 and MIRA-3) that evaluated the safety and…
GRI Bio Granted Patent for Proprietary Natural Killer T Cell Modulators for Prevention & Treatment of Inflammatory Conditions
GRI Bio, Inc. recently announced it has received a Decision to Grant notice from the Japan Patent Office (JPO) for the patent application No. 2023-000750…
Dupixent Approved in the US as the First-Ever Biologic Medicine for Patients With COPD
The US FDA has approved Dupixent (dupilumab) as an add-on maintenance treatment of adults with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic…
FDA Approves First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults
Bristol Myers Squibb recently announced the US FDA has approved COBENFY (xanomeline and trospium chloride), an oral medication for the treatment of schizophrenia in adults.…
Evaxion Significantly Expands Vaccine Development Collaboration With MSD
Evaxion Biotech A/S recently announced it has entered into an option and license agreement with MSD (tradename of Merck & Co., Inc.) for two preclinical…
Acumen Pharmaceuticals Extends Collaboration With Lonza to Add Drug Product Manufacturing of Sabirnetug for Early Alzheimer’s Disease
Acumen Pharmaceuticals, Inc. recently announced it has extended its collaboration with Lonza to enable the potential future commercial launch of sabirnetug (ACU193). Sabirnetug is the…
GRI Bio Receives Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621
GRI Bio, Inc. recently announced the authorization of its Clinical Trial Application (CTA) by the Australian Medicines and Healthcare products Regulatory Agency (MHRA) and the…
ImmunoPrecise Antibodies Advances Therapeutic Innovation With Groundbreaking Rabbit Antibody Developments
ImmunoPrecise Antibodies Ltd. (IPA) recently announced the clinical progress achieved with rabbit monoclonal antibodies designed and developed using IPA’s proprietary B Cell Select platform for…
Evonik Launches EUDRACAP Colon Functional Capsules for the Targeted Delivery of Oral Drugs
Evonik is expanding its EUDRACAP portfolio with a new functional, ready-to-fill capsule that enables the delivery of sensitive active ingredients to the ileo-colonic region. EUDRACAP…
Palisade Bio Provides Update on Progress Toward Launch of Phase 1 Human Clinical Study for Lead Program for the Treatment of Ulcerative Colitis
Palisade Bio, Inc. recently provided an update on its progress toward the launch of its Phase 1 human clinical study for PALI-2108 for the treatment of…
Sanner Group Acquires Gilero to Expand Global Medical Device Offering
Sanner Group has acquired Gilero LLC, a world class medical device design, development, and contract manufacturer headquartered in Durham, NC. The addition of Gilero will…
GoLiver Therapeutics Awarded Innovation in Biotherapies & Bioproduction Call for its GOCLINICALS Project Dedicated to Novel Stem Cell-Based Liver Therapy
GoLiver Therapeutics recently announced it has won the Innovations in Biotherapies and Bioproduction call for proposal launched by the French government to make France a…
